You will begin the trial after being admitted to the hospital for worsening heart failure (a condition where your heart cannot pump blood effectively, leading to fluid buildup in your body).

To qualify for the study, you must have been admitted to the hospital no more than 48 hours before joining the trial and still have significant fluid overload (at least 5 kg or 11 pounds of excess fluid) requiring intravenous diuretics.

You must have had a heart failure hospitalization in the previous 12 months and been taking an oral water pill (loop diuretic) for at least 1 month before this hospital admission.

You will be randomly assigned to receive either COR-1167 (an investigational medication) or a placebo (a solution that looks the same but contains no active ingredient).

If assigned to COR-1167, you will receive one of three different doses of the medication.

The medication or placebo will be given as a daily injection under the skin (subcutaneous injection) using a pre-filled syringe.

You will receive daily injections of either COR-1167 or placebo for a total of 4 weeks.

Throughout this period, medical staff will monitor your condition and collect data on several important measures:

During the 4-week treatment period, the following will be regularly measured:

Natriuresis: The amount of sodium excreted in your urine, which indicates how well your body is eliminating excess fluid.

Body weight: Regular weight measurements will track fluid loss.

NT-proBNP levels: Blood tests measuring a protein that increases when heart failure worsens.

KCCQ Total Symptom Score: You’ll complete questionnaires about your heart failure symptoms.

Left Atrial Volume Index (LAVi): Imaging tests to measure a specific heart chamber size, which can indicate heart failure severity.

Throughout the study, your safety will be closely monitored through:

Blood and urine tests: To check various body functions including kidney function.

Vital signs: Regular measurement of blood pressure, heart rate, breathing rate, and body temperature.

Physical examinations: To assess your overall health status.

Electrocardiogram (ECG): A test that records the electrical activity of your heart.

Monitoring for side effects: Any unusual symptoms or adverse events will be documented.

After completing the 4-week treatment period, a final set of assessments will be conducted.

Blood samples will be taken to check for anti-drug antibodies (proteins your body might produce in response to the study medication).

All the measurements taken during the study will be evaluated to determine how the different doses of COR-1167 affected your heart failure symptoms compared to placebo.